Articles

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX

The National and Kapodistrian University of Athens, Greece
Clínica Universidad de Navarra-CIMA, IDISNA, CIBERONC, Pamplona, Spain
Department of Oncology, University of Alberta Cross Cancer Institute, Edmonton, Alberta, Canada
QEII Health Sciences Center and Dalhousie University, Halifax, Nova Scotia, Canada
Service d’Hématologie et Thérapie Cellulaire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire (CHRU), Tours, France
St James’s Institute of Oncology, Leeds Teaching Hospitals NHS Trust and University of Leeds, UK
Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
Icon Cancer Care, South Brisbane, QLD, Australia
Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Department of Hematology, National Hospital Organization Disaster Medical Center of Japan, Tachikawa, Japan
Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France
Winship Cancer Institute, Emory University, Atlanta, GA, USA
Leukemia/Bone Marrow Transplant Program, University of British Columbia, Vancouver, Canada
CHU de Québec Research Center, Faculty of Medicine, Laval University, Canada
Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petah-Tikva, Israel
Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan
Yonsei University College of Medicine, Severance Hospital, Seoul, South Korea
Cabrini Hospital, Epworth HealthCare and Sir Peter MacCallum Department of Oncology, University of Melbourne, VIC, Australia
Gold Coast University Hospital, Southport, QLD, Australia
Institut Català d’Oncologia i Institut Josep Carreras, Hospital Germans Trias I Pujol, Barcelona, Spain
University of Calgary, Arnie Charbonneau Cancer Institute, Alberta, Canada
Icahn School of Medicine at Mount Sinai, New York, NY, USA
Janssen Research & Development, LLC, Spring House, PA, USA
Janssen Research & Development, LLC, Spring House, PA, USA
Janssen Research & Development, LLC, Raritan, NJ, USA
Janssen Research & Development, Beerse, Belgium
Janssen Research & Development, LLC, Spring House, PA, USA
Janssen Research & Development, LLC, Spring House, PA, USA
Genmab US, Inc, Princeton, NJ, USA
Janssen Research & Development, LLC, Spring House, PA, USA
Unite de Genomique du Myelome, IUC-Oncopole, Toulouse, France
Levine Cancer Institute/Atrium Health, Charlotte, NC, USA
Vol. 103 No. 12 (2018): December, 2018 https://doi.org/10.3324/haematol.2018.194282